CCE Stock UPDATES Coca-Cola Enterprises (CCE) 43.00 10/30/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 30, 2014 at 3:28 AM

Coca-Cola Enterprises (CCE) 43.00 $CCE

Third Quarter Earnings - Research Reports on Carter's, Skechers, Dana, Coca-Cola and Autoliv
PR Newswire - Tue Oct 28, 8:15AM CDT
Today, Analysts Review released its research reports regarding Carter's, Inc. (NYSE: CRI), Skechers USA Inc. (NYSE: SKX), Dana Holding Corporation (NYSE: DAN), Coca-Cola Enterprises Inc. (NYSE: CCE) and Autoliv, Inc. (NYSE: ALV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7493-100free.
ALV: 90.39 (-1.46), SKX: 54.15 (+0.07), DAN: 19.72 (-0.30), CRI: 78.24 (+0.12), CCE: 43.00 (-0.31)

Coca-Cola Enterprises Beats Earnings; Lowers Sales View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 11:10AM CDT
Coca-Cola Enterprises Inc. (CCE) announced dismal third-quarter 2014 earnings.
KO: 40.96 (+0.40), MNST: 98.65 (+1.20), GMCR: 147.87 (+1.21), CCE: 43.00 (-0.31)

Shares of CCE Down 7.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 23, 9:54AM CDT
SmarTrend identified a Downtrend for Coca-Cola Enterprises (NYSE:CCE) on September 5th, 2014 at $46.60. In approximately 2 months, Coca-Cola Enterprises has returned 7.64% as of today's recent price of $43.04.
CCE: 43.00 (-0.31)

Coca-Cola Enterprises tops 3Q earnings expectations
Automated Insights - Thu Oct 23, 7:01AM CDT
ATLANTA (AP) _ Coca-Cola Enterprises Inc. (CCE) on Thursday reported third-quarter net income of $238 million.
CCE: 43.00 (-0.31)

Coca-Cola Enterprises, Inc. Reports Third-Quarter 2014 Results and Full-Year Earnings Outlook
Business Wire - Thu Oct 23, 6:32AM CDT
--Net sales totaled $2.1 billion, down 11/2 percent on a reported basis, or down 31/2 percent on a currency-neutral basis; volume declined 4 percent.
CCE: 43.00 (-0.31)

Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
AVD: 10.85 (-0.04), CVCY: 10.78 (unch), CCE: 43.00 (-0.31), AIR: 25.43 (-0.06), GTLS: 46.29 (-0.88)

Coca-Cola Enterprises, Inc. Declares Regular Quarterly Dividend
Business Wire - Mon Oct 20, 3:05PM CDT
The Coca-Cola Enterprises (NYSE: CCE)(Euronext Paris: CCE) Board of Directors declared a regular quarterly dividend of 25 cents per share. The dividend is payable December 4, 2014 to shareowners of record on November 21, 2014.
CCE: 43.00 (-0.31)

Can Coca-Cola Enterprises (CCE) Surprise Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 1:20PM CDT
Coca-Cola Enterprises Inc. (CCE) is set to report the third-quarter fiscal 2014 results on Oct 23, before the market opens.
WWAV: 36.95 (+0.02), KO: 40.96 (+0.40), HSY: 94.06 (-1.47), CCE: 43.00 (-0.31)

Coca-Cola Enterprises Down 14.8% Since SmarTrend Downtrend Call (CCE)
Comtex SmarTrend(R) - Thu Oct 16, 9:34AM CDT
SmarTrend identified a Downtrend for Coca-Cola Enterprises (NYSE:CCE) on September 5th, 2014 at $46.60. In approximately 1 month, Coca-Cola Enterprises has returned 14.79% as of today's recent price of $39.71.
CCE: 43.00 (-0.31)

Zacks Industry Outlook Highlights: Unilever, Coca-Cola Enterprises, Kimberly-Clark, PepsiCo and Procter & Gamble
PR Newswire - Wed Oct 15, 8:30AM CDT
Today, Zacks Equity Research discusses the Consumer Staples (part 3), including Unilever plc (NYSE:UL-Free Report), Coca-Cola Enterprises, Inc. (NYSE:CCE-Free Report), Kimberly-Clark Corp. (NYSE:KMB-Free Report), PepsiCo Inc. (NYSE

EP-Free Report) and Procter & Gamble Co. (NYSE

G-Free Report).
KMB: 113.44 (-0.29), UL: 39.85 (-0.11), CCE: 43.00 (-0.31), PEP: 94.69 (-0.57)

Macroeconomic Factors Weigh on Consumer Staples Stocks - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:39AM CDT
Macroeconomic Factors Weigh on Consumer Staples Stocks - Zacks Analyst Interviews
DPS: 67.72 (-0.18), KO: 40.96 (+0.40), MDLZ: 34.93 (-0.36), KMB: 113.44 (-0.29), TAP: 72.90 (-0.70), PG: 86.54 (+0.07), UL: 39.85 (-0.11), CCE: 43.00 (-0.31), DEO: 116.28 (+0.24), K: 62.47 (-0.28), PEP: 94.69 (-0.57)

Macroeconomic Factors Weigh on Consumer Staples Stocks - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:39AM CDT
Macroeconomic Factors Weigh on Consumer Staples Stocks - Industry Outlook
DPS: 67.72 (-0.18), KO: 40.96 (+0.40), MDLZ: 34.93 (-0.36), KMB: 113.44 (-0.29), TAP: 72.90 (-0.70), PG: 86.54 (+0.07), UL: 39.85 (-0.11), CCE: 43.00 (-0.31), DEO: 116.28 (+0.24), K: 62.47 (-0.28), PEP: 94.69 (-0.57)

Are Cost-Control Measures Driving Consumer Staples? - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 3:37AM CDT
Are Cost-Control Measures Driving Consumer Staples? - Industry Outlook
MDLZ: 34.93 (-0.36), MKC: 69.32 (-0.45), GMCR: 147.87 (+1.21), KMB: 113.44 (-0.29), SYY: 38.21 (+0.01), LO: 61.22 (+0.19), KRFT: 56.91 (-0.34), CCE: 43.00 (-0.31), SJM: 102.52 (-1.39), PEP: 94.69 (-0.57), K: 62.47 (-0.28), DPS: 67.72 (-0.18), SBUX: 76.54 (-0.51), DNKN: 45.75 (-0.63), RAI: 62.22 (+0.20), KO: 40.96 (+0.40), BUD: 109.92 (-0.27), UN: 38.13 (-0.10), TAP: 72.90 (-0.70), TSN: 38.96 (-0.40), UL: 39.85 (-0.11), MO: 47.57 (+0.04), WWAV: 36.95 (+0.02), PM: 87.91 (-0.36), UNFI: 66.15 (+0.39), BGS: 28.69 (+0.24), PG: 86.54 (+0.07), GIS: 50.90 (-0.48)

How Will Coca-Cola Enterprises (CCE) Stock Be Affected Today by This Analyst Action?
at The Street - Mon Oct 06, 7:32AM CDT
Nomura Group upgraded Coca-Cola Enterprises (CCE) to 'neutral' from 'reduce' with a price target of $134.
CCE: 43.00 (-0.31)

Upgrade Alert for Coca-Cola Enterprises (CCE)
Comtex SmarTrend(R) - Mon Oct 06, 6:57AM CDT
Coca-Cola Enterprises (NYSE:CCE) was upgraded from Reduce to Neutral at Nomura today. The stock closed yesterday at $44.08 on volume of 3.2 million shares, above average daily volume of 1.8 million. Coca-Cola Enterprises (NYSE:CCE) has potential upside of 14.6% based on a current price of $44.08 and analysts' consensus price target of $50.53. Coca-Cola Enterprises shares should first meet resistance at the 200-day moving average (MA) of $46.04 and find additional resistance at the 50-day MA of $46.25.
CCE: 43.00 (-0.31)

Coca-Cola Enterprises, Inc. to Webcast Third-Quarter 2014 Earnings Conference Call
Business Wire - Thu Sep 25, 8:00AM CDT
Coca-Cola Enterprises (NYSE: CCE) (Euronext Paris: CCE) will release third-quarter 2014 earnings before the market opens on Thursday, October 23.
CCE: 43.00 (-0.31)

Look for Shares of Coca-Cola Enterprises to Potentially Rebound after Yesterday's 2.30% Sell Off
Comtex SmarTrend(R) - Tue Sep 23, 5:21PM CDT
Coca-Cola Enterprises (NYSE:CCE) traded in a range yesterday that spanned from a low of $45.03 to a high of $45.92. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $45.67 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CCE: 43.00 (-0.31)

Coca-Cola Enterprises Falls 2.30% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Sep 23, 5:20PM CDT
Coca-Cola Enterprises (NYSE:CCE) traded in a range yesterday that spanned from a low of $45.03 to a high of $45.92. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $45.67 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CCE: 43.00 (-0.31)

SmarTrend Watching for Potential Pullback in Shares of Coca-Cola Enterprises After 1.20% Gain
Comtex SmarTrend(R) - Fri Sep 19, 4:18PM CDT
Coca-Cola Enterprises (NYSE:CCE) traded in a range yesterday that spanned from a low of $45.78 to a high of $46.38. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $46.25 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CCE: 43.00 (-0.31)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

AI-Driven Lumi Transforms Car Dealership Interactions

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...